Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 1999 Jan;6(1):63–76.

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 1999, Cold Spring Harbor Laboratory Press

PMC Copyright notice

Effects of an NO synthase inhibitor or hemoglobin on long-term enhancement produced by tACPD paired training. (A) N^ω-nitro-arginine (100 μm) did not block long-term enhancement by tACPD paired with weak stimulation (█) (172.4 ± 19.3%, n = 8, t = 3.75, P < 0.01). The EPSP at a second control pathway in the same slice, which received tACPD alone, was stable (□) (101.1 ± 24.5%). (B) Hemoglobin (20 μm) completely prevented long-term enhancement produced by tACPD paired training (█) (72.0 ± 19.5%, n = 7). The EPSP at a second control pathway in the same slice was stable (□) (104.3 ± 36%). The average prevalues were 0.30 mV/msec (paired), 0.26 (control) (A) and 0.28 (paired), 0.30 (control) (B).